Construction of anticancer drug incorporated aptamer-functionalized cationic β-lactoglobulin: induction of cell cycle arrest and apoptosis in colorectal cancer DOI
Zhipeng Zhang, Tianran Zhang, Zimeng Li

et al.

Journal of Biomaterials Science Polymer Edition, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 20

Published: Oct. 16, 2024

Nanoscale drug delivery systems that are both multifunctional and targeted have been developed using proteins as a basis, thanks to their attractive biomacromolecule properties. A novel nanocarrier, aptamer (AS1411)-conjugated β-lactoglobulin/poly-l-lysine (BLG/Ap/PL) nanoparticles, was in this study. To unique formulation, the as-prepared nanocarrier blends distinctive features of an chemotherapeutic targeting agent with those protein nanocarriers. By loading cabazitaxel (CTX) onto nanocarriers, therapeutic potential BLG/Ap/PL could be demonstrated. The CTX-loaded (CTX@BLG/Ap/PL) showed regulated release profile acidic milieu, which improve efficacy cancer cells high encapsulation up 93%. However, compared free CTX, CTX@BLG/Ap/PL killed colorectal HCT116 higher at 24 48 h. Further investigation confirms apoptosis by acridine orange ethidium bromide (AO/EB), DAPI staining morphological changes, chromatin condensation, membrane blebbing treated cell through flow cytometry displayed percentages apoptosis. Cell cycle analysis revealed induced sub-G1 G2/M phase (apoptosis) Annexin V/propidium iodide (PI) confirmed induces cells. Overall, study proved had several advantages over drugs promise solution clinical problems associated antitumor systems.

Language: Английский

Aptamer-Based Smart Targeting and Spatial Trigger–Response Drug-Delivery Systems for Anticancer Therapy DOI Creative Commons

Dongsik Park,

Su Jin Lee, Jee-Woong Park

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(1), P. 187 - 187

Published: Jan. 15, 2024

In recent years, the field of drug delivery has witnessed remarkable progress, driven by quest for more effective and precise therapeutic interventions. Among myriad strategies employed, integration aptamers as targeting moieties stimuli-responsive systems emerged a promising avenue, particularly in context anticancer therapy. This review explores cutting-edge advancements targeted drug-delivery systems, focusing on platforms enhanced spatial aptamer-based we delve into versatile applications aptamers, examining their conjugation with gold, silica, carbon materials. The synergistic interplay between these materials is discussed, emphasizing potential achieving delivery. Additionally, explore an emphasis Tumor microenvironment-responsive nanoparticles are elucidated, capacity to exploit dynamic conditions within cancerous tissues controlled release detailed. External strategies, including ultrasound-mediated, photo-responsive, magnetic-guided examined role effects. integrates diverse approaches precision medicine, showcasing revolutionize

Language: Английский

Citations

18
Breaking barriers in cancer management: The promising role of microsphere conjugates in cancer diagnosis and therapy DOI Creative Commons
Ashutosh Gupta, Sanjay Kulkarni, Soji Soman

et al.

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 665, P. 124687 - 124687

Published: Sept. 10, 2024

Language: Английский

Citations

9
Designing Multivalent Aptamers: Recent Advancements in Diagnostic and Therapeutic Approaches for Cancer Treatment DOI
Zahra Moradi, Khalil Abnous, Seyed Mohammad Taghdisi

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106614 - 106614

Published: Jan. 1, 2025

Language: Английский

Citations

1
Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges DOI Open Access
Wojciech Szymanowski, A. Szymanowska, Anna Bielawska

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(21), P. 5300 - 5300

Published: Nov. 6, 2023

Ovarian cancer (OC) is the most common lethal gynecologic cause of death in women worldwide, with a high mortality rate and increasing incidence. Despite advancements treatment, OC patients still die from their disease due to late-stage diagnosis, lack effective diagnostic methods, relapses. Aptamers, synthetic, short single-stranded oligonucleotides, have emerged as promising anticancer therapeutics. Their ability selectively bind target molecules, including cancer-related proteins receptors, has revolutionized drug discovery biomarker identification. Aptamers offer unique insights into molecular pathways involved development progression. Moreover, they show immense potential delivery systems, enabling targeted therapeutic agents cells while minimizing off-target effects reducing systemic toxicity. In context OC, integration aptamers non-coding RNAs (ncRNAs) presents an opportunity for precise efficient gene targeting. Additionally, conjugation nanoparticles allows accurate ncRNAs specific cells, tissues, or organs. this review, we will summarize use challenges associated alone aptamer–ncRNA conjugates, nanoparticles, multivalent aptamer-based therapeutics treatment OC.

Language: Английский

Citations

12
Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy DOI Creative Commons
Theivendren Panneerselvam, Selvaraj Kunjiappan, Parasuraman Pavadai

et al.

ACS Measurement Science Au, Journal Year: 2024, Volume and Issue: 5(1), P. 31 - 55

Published: Nov. 15, 2024

Cancer immunotherapy is an innovative way of treating cancer by stimulating individual cells to overcome cancer. Widespread biomedical studies were carried out with the aim exploring therapeutics, and this review spotlights some mechanisms in which it was developed, namely immune checkpoint inhibitors (E.G PD-1/PD-L1, CTLA-4), adoptive cell therapy (e.g., CAR T-cell therapy), vaccines. Although has shown clinical benefit a number types, including melanoma non-small-cell lung cancer, several challenges have dampened enthusiasm for approach, from differing patient response rates toxicities. Nanotechnology drug delivery systems must play role overcoming same. enables increased specificity controlled release, improved solubility bioavailability, can treat tumor specifically, localized at disease site decreases systemic toxicity. The also features advances construction lipid-based, polymeric, inorganic nanoparticles that improve stability allow cotherapeutic agents. Nanotechnology-based be used alone or combination assist improving response, gaining access microenvironment, biological barriers. Thus, nano-DDS both safe effective preclinical studies, ongoing trials they are capable increasing therapeutic index anticancer drugs. Lastly, discusses current regulatory issues advancing these technologies highlights importance further research devise appropriate methodology efficient functionalization nanotechnology individualized solutions treatment.

Language: Английский

Citations

4
Bio-inspired, programmable biomacromolecules based nanostructures driven cancer therapy DOI
Rahul Sharma, Unnati Modi, Rahul Kumar

et al.

Biomaterials Advances, Journal Year: 2025, Volume and Issue: 171, P. 214235 - 214235

Published: Feb. 15, 2025

Language: Английский

Citations

0
Aptamer based immunotherapy: a potential solid tumor therapeutic DOI Creative Commons
Sarmilah Mathavan,

Yifang Tam,

Khairul Mohd Fadzli Mustaffa

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 17, 2025

Aptamer-based immunotherapy can be a new hope for treating solid tumors with personalized and specific approaches toward cancer therapies. Aptamers are small synthetic single-stranded nucleic acids that may bring in paradigm shift tumors. These highly selective drugs applied cellular immunotherapy, cytokine modulation, immune checkpoint suppression. This review provides an overview of the recent advances aptamer-based technologies key clinical trials involving AON-D21 AM003. potently active regulation tumor targeting. However, aptamer stability bioavailability seriously compromised by issues relating to renal clearance rapid degradation through nucleases. The latter reviewed here along novel improvements, some which involve chemical modifications greatly enhance prolong circulation time; exemplary such PEGylation, cholesterol conjugation, synthesis circular acids. regulatory aspect is also crucial. For example, addition strategies prevent drug-drug interactions (DDIs) remediation medications, this paper underscores need risk assessment, particularly because immunogenicity organ failure. use aptamers expanded development SOMAmers, X-aptamers, bioinformatics. To make major part treatment, future research should concentrate more on resolving existing expanding their beneficial uses.

Language: Английский

Citations

0
Wolf in Sheep’s Clothing: Taming Cancer’s Resistance with Human Serum Albumin? DOI Creative Commons
Iga Stukan, Anna Żuk,

Kamila Pukacka

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 3493 - 3525

Published: March 1, 2025

Human serum albumin (HSA) has emerged as a promising carrier for nanodrug delivery, offering unique structural properties that can be engineered to overcome key challenges in cancer treatment, especially resistance chemotherapy. This review focuses on the cellular uptake of albumin-based nanoparticles and modifications enhance their ability bypass mechanisms, particularly multidrug type 1 (MDR1), by improving targeting cells. In our approach, we integrate chemical albumin, its interactions with cells, surface delivery systems enable those related MDR1, precisely target receptors cells improve treatment efficacy. We discuss while well-established such gp60 gp18/30 are crucial transcytosis, biology remains underexplored, limiting translational potential. Additionally, explore potential emerging targets, cluster differentiation 44 (CD44), (CD36) transferrin receptor TfR1, well advantages using dimeric forms (dHSA) further resistant Drawing from clinical examples, including success albumin-bound paclitaxel (Abraxane) new formulations like Pazenir Fyarro (for Sirolimus), identify gaps current knowledge propose strategies optimize systems. conclusion, nanoparticles, when tailored appropriate modifications, have By enhancing albumin's efficiently deliver therapeutic agents, these carriers represent approach addressing one oncology's most persistent challenges, substantial outcomes.

Language: Английский

Citations

0
Advancing ovarian cancer management: Role of nucleic acid biomarkers and novel therapeutic approaches DOI

Rutuja Deshmukh,

Sharav Desai,

Vipul Patel

et al.

Gene Reports, Journal Year: 2025, Volume and Issue: unknown, P. 102241 - 102241

Published: May 1, 2025

Language: Английский

Citations

0
Aptamers for the Delivery of Plant-Based Compounds: A Review DOI Creative Commons
Joana Gamboa, Pedro Lourenço, Carla Cruz

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(4), P. 541 - 541

Published: April 14, 2024

Natural compounds have a high potential for the treatment of various conditions, including infections, inflammatory diseases, and cancer. However, they usually present poor pharmacokinetics, low specificity, even toxicity, which limits their use. Therefore, targeted drug delivery systems, typically composed carrier targeting ligand, can enhance natural product selectivity effectiveness. Notably, aptamers—short RNA or single-stranded DNA molecules—have gained attention as promising ligands in since are simple to synthesize modify, tissue permeability, stability, wide array available targets. The combination products, namely plant-based compounds, with system utilizing aptamers agents represents an emerging strategy that has broaden its applications. This review discusses well new trends developments utilization field medicine.

Language: Английский

Citations

3